modelB02BD10
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | VonWillebrandFactor | |
| ATC code: | B02BD10 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 0.047 | L |
| clearance: | 0.041 | L/h/kg |
| other parameters in model implementation | ||
Von Willebrand factor (vWF) is a large multimeric glycoprotein important in hemostasis. It mediates platelet adhesion to sites of vascular injury and serves as a carrier protein for coagulation factor VIII. Plasma-derived and recombinant vWF products are used primarily in the treatment and prevention of bleeding episodes in patients with von Willebrand disease, a congenital or acquired bleeding disorder. vWF is an approved drug for clinical use today.
Pharmacokinetics
Pharmacokinetics in adults with severe von Willebrand disease following intravenous administration of plasma-derived von Willebrand factor concentrate (e.g., Wilate), using a one-compartment model.
References
Nestorov, I, et al., & Rogge, M (2015). Population pharmacokinetics of recombinant factor VIII Fc fusion protein. Clinical pharmacology in drug development 4(3) 163–174. DOI:10.1002/cpdd.167 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27140796
Gritsch, H, et al., & Turecek, PL (2022). Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease. Journal of blood medicine 13 649–662. DOI:10.2147/JBM.S377126 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36405429
Bauer, A, et al., & Wolfsegger, M (2023). Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3. Journal of blood medicine 14 399–411. DOI:10.2147/JBM.S395845 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37332615
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)